DSM-V Revisions Could Open - Or Close - Opportunities For Drug Industry
Drug firms with a major stake in neurologic and psychiatric drug development are closely monitoring the psychiatric profession as it goes through its once-a-generation revamp of the Diagnostic and Statistical Manual of Mental Disorders
You may also be interested in...
Experts convened by FDA to discuss female sexual dysfunction disorders, including problems with desire and arousal, settle on endpoints contrary to new DSM, but are in line with trials of Sprout’s flibanserin, the leading drug in development.
The recent American Psychiatric Association annual meeting featured a lecture on drug development by Sanofi’s former head of CNS development Robert Lenox. In a post-meeting interview, he weighs in on the highs and lows of psychiatric drug development, as well as the newly released fifth edition of the Diagnostic and Statistical Manual of Mental Disorders.
Shire targets specialist segments of vast primary care populations, with focus on areas of unmet need.